✦ LIBER ✦

Comparison of 5-fluorouracil with 5-fluorouracil, cyclophosphamide, and methotrexate in metastatic colorectal carcinoma

✍ Scribed by Frederick Richards II; Thomas L. Pajak; Miles R. Cooper; Charles L. Spurr

Publisher: John Wiley and Sons
Year: 1975
Tongue: English
Weight: 289 KB
Volume: 36
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197511)36:5<1589::aid-cncr2820360509>3.0.co;2-z

No coin nor oath required. For personal study only.

✦ Synopsis

Thirty-eight patients with metastatic colorecal carcinoma were treated with 5-fluorouracil (5-FU), and 38 patients were treated with the combination of 5-FU, cyclophosphamide, and methotrexate. In terms of percent response, response duration, and survival there was no apparent difference between the two regimens. Combination chemotherapy was found to be effective in 6 of 16 patients refractory to treatment with 5-FU alone, but was associated with more morbidity.

📜 SIMILAR VOLUMES

Therapy of advanced colorectal carcinoma

Therapy of advanced colorectal carcinoma with 5-fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate

✍ Douglas R. White; Frederick Richards II; Hyman B. Muss; M. Robert Cooper; Charle 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB 👁 1 views

A comprehensive review of 5-fluorouracil

A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

✍ David Machover 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

## Background: Colorectal carcinoma is the third leading cause of cancer-related death. the primary treatment for patients with metastatic colorectal carcinoma is systemic chemotherapy with 5-fluorouracil (5-fu) and leucovorin (lv), a biomodulator of 5-fu that has been shown to enhance its activity

Comparison of 5-fluorouracil alone, 5-fl

Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma

✍ Robert S. Witte; Avital Cnaan; Edward G. Mansour; Edward Barylak; Jules E. Harri 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Cyclophosphamide versus cyclophosphamide

Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: A randomized trial

✍ Hyman B. Muss; Virginia Howard; Frederick Richards Ii; Douglas R. White; Don V. 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 364 KB 👁 1 views

Thirty-two evaluable patients with metastatic carcinoma of the prostate were entered into a prospective randomized trial comparing cyclophosphamide (CYC) with a combination of cyclophosphamide, methotrexate, and fluorouracil (CMF). Progressive disease after endocrine manipulation was noted in 97% (3

5-Fluorouracil–induced small bowel toxic

5-Fluorouracil–induced small bowel toxicity in patients with colorectal carcinoma

✍ Jacob Lokich 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 2 views

5-Fluorouracil-induced small bowel toxic

5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma

✍ Farid Fata; Ilan G. Ron; Nancy Kemeny; Eileen O'Reilly; David Klimstra; David P. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 499 KB 👁 2 views

## BACKGROUND. Diarrhea and oral mucositis are the most frequently reported gastrointestinal side effects caused by 5-fluorouracil (5-FU). Diarrhea may be severe in 10 -30% of patients and is schedule-dependent. 5-FU-induced gastrointestinal toxicity predominantly affects the upper and the lower g